Organisation paid for research Program year 2025 Source: CMS Open Payments

The Oregon CLNC

Neither a doctor nor a teaching hospital

Research payments

$141,551

204 payments

Through program year 2025, The Oregon CLNC is reported as receiving $141,551 in research payments, across 204 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$61,219	107
2024	Research	$26,565	21
2023	Research	$17,473	5
2022	Research	$10,569	6
2021	Research	$6,748	16
2020	Research	$9,078	20
2019	Research	$9,899	29

Breakdown

Who paid Research payments · program years 2019–2025

Janssen Research & Development, LLC $66,122 69 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $46,280 36 payments
Boehringer Ingelheim International GmbH $26,493 72 payments
Boehringer Ingelheim Limited $1,358 13 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $1,298 14 payments

Studies the money was for Research payments · program years 2019–2025

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) $39,196 28 payments
DCRI Registry Study $38,937 13 payments
PDE4 Phase III trial in IPF patients $22,194 18 payments
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI) $15,963 27 payments
78934804Crd2001 $8,200 8 payments
Idiopathic Pulmonary Fibrosis Prospective Outcome Registry $4,894 13 payments
PDE4 Phase III trial in PF ILD $2,907 2 payments
Nintedanib in PF-ILD (extension) $2,871 40 payments
Cnto1959crd3004 $2,763 6 payments
Nintedanib - PF-ILD $1,298 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.